Probatebeta
Target

SCN5A

Sodium channel protein type 5 subunit alpha

As of the edition of 20 October 2026, SCN5A (sodium channel protein type 5 subunit alpha, UniProt Q14524) has 62 drugs tested at it and 21 companies on the list, 1 on route A and 9 on route B.

Sources: UniProt, ClinicalTrials.gov, ChEMBL, FDA Orange Book and Purple Book, Pharos.

The protein

UniProt
Q14524
How well studied
Drug target: an approved drug acts on it
Where it sits in the cell
In more than one place
Solved structures
16
Disease areas
Nervous system; Mental health; Heart and blood vessels; Injuries; Cancer; Bones, joints and muscles; Nutrition and metabolism; Urinary and reproductive
Registered trials of its drugs
2,781

Drugs at this target

StatusCount
Marketed49
Active3
Went quiet7
Stopped1
Withdrawn from market2
Total62
DrugStatusFurthest phaseUS protection
LidocaineMarketedPhase 4none listed
RopivacaineMarketedPhase 4none listed
TopiramateMarketedPhase 4none listed
LamotrigineMarketedPhase 4none listed
CarbamazepineMarketedPhase 4none listed
LacosamideMarketedPhase 4Ended 2026
RiluzoleMarketedPhase 4none listed
TetracaineMarketedPhase 4none listed
Eslicarbazepine acetateMarketedPhase 4Ended 2026
RanolazineMarketedPhase 4none listed
ZonisamideMarketedPhase 4none listed
PhenytoinMarketedPhase 4none listed

12 of 62 drugs, the most tested first.

Companies at this target

Where the company standsCompanies
Route A1
Route B9
Engaged6
Undetermined5
Total on the list21
Three companies on route A or B, with the route only
CompanyRoute
NovartisRoute B
MenariniRoute B
Cipher PharmaceuticalsRoute B

The other 18 companies at SCN5A

In the product

21 companies in all; 18 are not named here, and no score is.

See the 21 companies at SCN5A, ranked, with the facts behind eachRequest access. Nothing is shown until you do.

More drugs at SCN5A

Other targets in nervous system

Companies holding approvals at SCN5A